Pfizer, Summit Therapeutics
Q4 2024 Earnings Call Transcript February 24, 2025 Operator: Good morning and welcome to Summit Therapeutics Fourth Quarter and Year End 2024 Earnings and Update Call. All participants will be in ...
Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...
Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.
Summit Therapeutics shares are dropping Monday morning as it reported a fourth-quarter adjusted loss nearly double that of ...
The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...
Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...
Over the last year, a good number of insiders have significantly increased their holdings in Summit Therapeutics ...
1don MSN
We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to ...
Clinical data from Indaptus’ ongoing Phase 1 trial evaluating Decoy20 in advanced solid tumors.
SMMT's Q4 results meet estimates. The company signs a deal with Pfizer that expands ivonescimab's development beyond the NSCLC indication.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback